menu
    • menu
    [{"orgOrder":0,"company":"New Approaches to Neuroblastoma Therapy Consortium","sponsor":"United Therapeutics | Jubilant DraxImage Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"Azedra","moa":"SLC6A2 | SPECT","graph1":"Oncology","graph2":"Phase II","graph3":"New Approaches to Neuroblastoma Therapy Consortium","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"New Approaches to Neuroblastoma Therapy Consortium \/ United Therapeutics | Jubilant DraxImage Inc","highestDevelopmentStatusID":"8","companyTruncated":"New Approaches to Neuroblastoma Therapy Consortium \/ United Therapeutics | Jubilant DraxImage Inc"}]

    Find Clinical Drug Pipeline Developments & Deals for Azedra

    Menu

    Azedra

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            New Approaches to Neuroblastoma Therapy Consortium

                            Country arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            New Approaches to Neuroblastoma Therapy Consortium

                            Country arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azedra,Vorinostat,Dinutuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : United Therapeutics | Jubilant DraxImage Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab

                            Details : 131-I Iobenguane is a Radiolabeled Compound drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Neuroblastoma.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            December 03, 2025

                            Lead Product(s) : Azedra,Vorinostat,Dinutuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : United Therapeutics | Jubilant DraxImage Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.